VANCOUVER, BC, July 5, 2022 /CNW/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) has appointed Dr. Robert E. W. Hancock, the co-founder of Asep Inc, as CEO and Chairman of the company effective immediately. Dr. Hancock replaces Rudy Mazzocchi, the former CEO and Chairman, who resigned for health reasons. Dr. Hancock said, “We wish Rudy well and sincerely thank him for his invaluable service and contributions to the Society.

Dr. Hancock is the co-founder of Asep Inc. and a world expert in infectious diseases. In recognition of his research, Dr. Hancock has received numerous awards and honours, including the Prix Galien (the highest honor for pharmaceutical research and innovation in Canada), the Killam Prize (a prize from the Conseil des Arts du Canada for Health Research), Michael Smith CIHR Researcher of the Year, the ICAAC Aventis Antimicrobial Research Award (the world’s most prestigious award for antimicrobial research) and in 2001 he was inducted as an Officer of the Order of Canada (from Canada second highest award).

Dr Hancock will step down as Chief Operating Officer and be replaced by Timothy Murphy, current member of the Company’s Board of Directors. Mr. Murphy is an experienced business lawyer and executive with a strong background in mergers and acquisitions, intellectual property and technology licensing.


Asep Inc. is dedicated to solving antibiotic failure by developing new solutions for significant unmet medical needs. The company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) which are both in the advanced development of the two proprietary diagnostic tools, enabling the early and rapid identification of severe sepsis as well as broad-spectrum therapies agents to combat multidrug-resistant biofilm infections.

Sepset Biosciences Inc. is developing diagnostic technology that involves a patient’s gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetEmergency room is a blood-based gene expression test that is simple to perform and results are obtained in approximately one hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate treatments and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc.’s peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, otolaryngology, sinusitis, orthopaedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.


This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. These statements, including, but not limited to, the successful completion of clinical testing of our Sepsis diagnostic test and its anticipated filing for regulatory approval; and conducting preclinical studies on our lead drug, in the hope that this will lead to accelerated clinical trials. Various assumptions were used in drawing the conclusions or making the predictions contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management as of the date they are made and are subject to various risks (including the risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the company profile at and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. applicable expressly so requires.

SOURCEASEP Medical Holdings Inc.

For further information: Tim Murphy, Chief Operating Officer, Asep Medical Holdings Inc., E. [email protected]T. +1 (778) 600-0509


Comments are closed.